ELN-128 (Early post-MI remodeling biology). Early post-MI, post-reperfusion anti-miR-128 candidate designed to lower the risk of progression to heart failure in high-risk MI patients. A single SC dose 2 hours post-reperfusion improved LV ejection fraction, reduced ventricular volumes, and decreased infarct size over 28 days in mice. RNA-seq confirmed restoration of oxidative phosphorylation and suppression of inflammatory pathways. Does not rely on RNase H or RISC.

ELN-128 expansion biology (DMD cardiomyopathy model). Translational proof-of-concept for the anti-miR-128 mechanism in a clinically relevant pig DMD model. 8-week SC treatment improved cardiac function in a chronic cardiac failure phenotype, improved cardiac output, and reduced cardiac damage markers. Same chemistry and dosing route as the lead post-MI program.

ELN-33 (Dry AMD). Anti-miR-33a program targeting cholesterol efflux and retinal inflammation biology. Systemic SC dosing reaches retina in NHP. Supports evaluation of a systemic, non-intravitreal approach.